litlas
Log inCreate account

Sylvie Négrier

Active 1989–2025

Also published as
Sylvie Negrier
83
Papers
30,976
Citations
59
h-index
81
i10-index

Citations

Citations per year for Sylvie Négrier1956: 3 citations1990: 1 citations1991: 1 citations1992: 5 citations1993: 9 citations1994: 8 citations1995: 14 citations1996: 7 citations1997: 15 citations1998: 29 citations1999: 39 citations2000: 40 citations2001: 39 citations2002: 44 citations2003: 54 citations2004: 50 citations2005: 65 citations2006: 64 citations2007: 171 citations2008: 271 citations2009: 347 citations2010: 340 citations2011: 336 citations2012: 333 citations2013: 362 citations2014: 263 citations2015: 229 citations2016: 222 citations2017: 201 citations2018: 193 citations2019: 725 citations2020: 845 citations2021: 645 citations2022: 467 citations2023: 356 citations2024: 471 citations2025: 178 citations2026: 10 citations1957–1989: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,339 citing papers, 27.1% of this breakdownChina: 694 citing papers, 8% of this breakdownFrance: 647 citing papers, 7.5% of this breakdownItaly: 543 citing papers, 6.3% of this breakdownUnited Kingdom: 507 citing papers, 5.9% of this breakdownGermany: 404 citing papers, 4.7% of this breakdownJapan: 331 citing papers, 3.8% of this breakdownCanada: 311 citing papers, 3.6% of this breakdownNetherlands: 262 citing papers, 3% of this breakdownSpain: 260 citing papers, 3% of this breakdownAustralia: 198 citing papers, 2.3% of this breakdownBelgium: 176 citing papers, 2% of this breakdown
0%27.1%Other 22.8%

Institutions

Fields

  • Medicine73.7%
  • Biochemistry, Genetics and Molecular Biology16.3%
  • Immunology and Microbiology6.1%
  • Mathematics0.7%
  • Computer Science0.6%
  • Engineering0.5%
  • Other2.1%

Topics

  • Renal cell carcinoma treatment11.7%
  • Cancer Immunotherapy and Biomarkers9%
  • Immunotherapy and Immune Responses3.4%
  • Renal and related cancers3.4%
  • CAR-T cell therapy research2.9%
  • Angiogenesis and VEGF in Cancer2.9%
  • Other66.7%

Coauthors

All papers

Open in search
  1. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, Brian I. Rini, Laurence Albigès, Matthew T. Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Négrier, Motohide Uemura, Jae L. Lee, Aleksandr Vasiliev, Wilson H. Miller, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Jens Bedke, B. Yа. Alekseev, Jing Wang, Mariangela Mariani, Paul B. Robbins, Aleksander Chudnovsky, Camilla Fowst, Subramanian Hariharan, Bo Huang, Alessandra di Pietro, Toni K. Choueiri - New England Journal of Medicine 2019 cited by 2,550

  2. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Sindy T. Kim, Isan Chen, Paul Bycott, Charles M. Baum, Robert A. Figlin - New England Journal of Medicine 2007 cited by 5,756

  3. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

    Authors: Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Négrier, Christine Chevreau, E Solska, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sara M. Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M. Bukowski - New England Journal of Medicine 2007 cited by 4,784

  4. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

    Authors: Jedd D. Wolchok, Bart Neyns, Gerald P. Linette, Sylvie Négrier, Jose Lutzky, L. Thomas, William Waterfield, Dirk Schadendorf, Michael Smylie, Troy H. Guthrie, Jean‐Jacques Grob, Jason Chesney, Kevin M. Chin, Kun Chen, Axel Hoos, Steven O’Day, Célèste Lebbé - The Lancet Oncology 2009 cited by 1,187

  5. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    Authors: Brian I. Rini, Bernard Escudier, Piotr Tomczak, А. Д. Каприн, Cezary Szczylik, Thomas E. Hutson, M. Dror Michaelson, В. А. Горбунова, Martin Gore, И. Г. Русаков, Sylvie Négrier, Yen-Chuan Ou, Daniel Castellano, Ho Yeong Lim, Hirotsugu Uemura, Jamal Tarazi, David Cella, Connie Chen, Brad Rosbrook, Sinil Kim, Robert J. Motzer - The Lancet 2011 cited by 1,849

  6. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Authors: Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin - Journal of Clinical Oncology 2009 cited by 2,189

  7. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

    Authors: Robert J. Motzer, Bernard Escudier, Piotr Tomczak, Thomas E. Hutson, M. Dror Michaelson, Sylvie Négrier, Stéphane Oudard, Martin Gore, Jamal Tarazi, Subramanian Hariharan, Connie Chen, Brad Rosbrook, Sinil Kim, Brian I. Rini - The Lancet Oncology 2013 cited by 745

  8. Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

    Authors: Jaafar Bennouna, Emmanuelle Bompas, Eve Marie Neidhardt, Frédéric Rolland, Irène Philip, Céline Galéa, Samuel Salot, Soraya Saïagh, Marie Audrain, Marie Rimbert, Sylvie Lafaye-de Micheaux, Jérôme Tiollier, Sylvie Négrier - Cancer Immunology Immunotherapy 2008 cited by 239

  9. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Authors: Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, Gloria Hofilena, Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski - Journal of Clinical Oncology 2009 cited by 1,083

  10. Uveal melanoma: In the era of new treatments

    Authors: Mylène Wespiser, Eve‐Marie Neidhardt, Sylvie Négrier - Cancer Treatment Reviews 2023 cited by 49

  11. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

    Authors: Ronan Flippot, Cécile Dalban, Brigitte Laguerre, Delphine Borchiellini, Gwénaëlle Gravis, Sylvie Négrier, Christine Chevreau, Florence Joly, Lionnel Geoffrois, Sylvain Ladoire, Hakim Mahammedi, Frédéric Rolland, Marine Gross‐Goupil, Élise Deluche, Frank Priou, Mathieu Laramas, Philippe Barthélémy, Bérengère Narciso, Nadine Houédé, Stéphane Culine, Stéphane Oudard, Marina Chenot, Florence Tantot, Sylvie Chabaud, Bernard Escudier, Laurence Albigès - Journal of Clinical Oncology 2019 cited by 163

  12. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma

    Authors: Laurence Albigès, Philippe Barthélémy, Marine Gross‐Goupil, Sylvie Négrier, Michael N. Needle, Bernard Escudier - Annals of Oncology 2020 cited by 57

  13. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

    Authors: J-F Rossi, Sylvie Négrier, Nicholas D. James, Ivo Kocák, Robert D. Hawkins, Hugh M. Davis, Uma Prabhakar, Xiang Qin, Peter F.A. Mulders, Birge Berns - British Journal of Cancer 2010 cited by 188

  14. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial

    Authors: Serge Leyvraz, Sophie Piperno‐Neumann, Stefan Suciu, J.F. Baurain, Marcin Zdzienicki, Alessandro Testori, Ernest Marshall, M. E. Scheulen, Thomas Jouary, Sylvie Négrier, Jan B. Vermorken, Eckhart Kaempgen, Xavier Durando, Dirk Schadendorf, Ravichandra Karra Gurunath, Ulrich Keilholz - Annals of Oncology 2014 cited by 147

  15. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

    Authors: Christopher Montemagno, Anaïs Hagege, Delphine Borchiellini, Brice Thamphya, Olivia Rastoin, Damien Ambrosetti, Juan Iovanna, Nathalie Rioux-Leclercq, Camillo Porta, Sylvie Négrier, Jean-­Marc Ferrero, Emmanuel Chamorey, Gilles Pagès, Maeva Dufies - OncoImmunology 2020 cited by 66

  16. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas

    Authors: Jonathan Thouvenin, Omar Alhalabi, Maria I. Carlo, Lucía Carril-Ajuria, Laure Hirsch, Nieves Martínez Chanzá, Sylvie Négrier, Luca Campedel, Dylan J. Martini, Delphine Borchiellini, Jad Chahoud, Massimo Lodi, Philippe Barthélémy, Elshad Hasanov, Andrew W. Hahn, Thierry Gil, Srinivas R. Viswanathan, Ziad Bakouny, Pavlos Msaouel, Mehmet Asım Bilen, Toni K. Choueiri, Laurence Albigès, Nizar M. Tannir, Gabriel G. Malouf - The Oncologist 2022 cited by 37

  17. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

    Authors: Sylvie Négrier, Bernard Escudier, Christine Lasset, Jean‐Yves Douillard, J. Savary, Christine Chevreau, Alain Ravaud, A. Mercatello, J Pény, Mireille Mousseau, Thierry Philip, Thomas Tursz - New England Journal of Medicine 1998 cited by 969

  18. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis

    Authors: Bernard Escudier, Vincent Molinié, Sergio Bracarda, Pablo Maroto, Cezary Szczylik, Paul Nathan, Sylvie Négrier, Claudia Weiß, Camillo Porta, Viktor Grünwald, Laurence Albigès - European Journal of Cancer 2016 cited by 92

  19. Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression

    Authors: Lindsay S. Cooley, Justine Rudewicz, Wilfried Souleyreau, Andrea Emanuelli, Arturo Álvarez-Arenas, Kim Clarke, Francesco Falciani, Maeva Dufies, Diether Lambrechts, Elodie Modave, Domitille Chalopin-Fillot, Raphaël Pineau, Damien Ambrosetti, Jean‐Christophe Bernhard, Alain Ravaud, Sylvie Négrier, Jean-­Marc Ferrero, Gilles Pagès, Sébastien Benzekry, Macha Nikolski, Andréas Bikfalvi - Molecular Cancer 2021 cited by 55

  20. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas

    Authors: Omar Alhalabi, Jonathan Thouvenin, Sylvie Négrier, Yann Vano, Luca Campedel, Elshad Hasanov, Ziad Bakouny, Andrew W. Hahn, Mehmet Asım Bilen, Pavlos Msaouel, Toni K. Choueiri, Srinivas R. Viswanathan, Kanishka Sircar, Laurence Albigès, Gabriel G. Malouf, Nizar M. Tannir - The Oncologist 2023 cited by 36

  21. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

    Authors: Bernard Escudier, Joaquim Bellmunt, Sylvie Négrier, Emilio Bajetta, Bohuslav Melichar, Sergio Bracarda, Alain Ravaud, Sophie Golding, Sangeeta Jethwa, Vesna Šneller - Journal of Clinical Oncology 2010 cited by 808

  22. The CXCL7/CXCR1/2 Axis Is a Key Driver in the Growth of Clear Cell Renal Cell Carcinoma

    Authors: Renaud Grépin, Mélanie Guyot, Sandy Giuliano, Marina Boncompagni, Damien Ambrosetti, Emmanuel Chamorey, Jean‐Yves Scoazec, Sylvie Négrier, Hélène Simonnet, Gilles Pagès - Cancer Research 2013 cited by 124

  23. Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial

    Authors: Toni K. Choueiri, Konstantin Penkov, Hiroji Uemura, Matthew T. Campbell, Sumanta K. Pal, Christian Kollmannsberger, J.L. Lee, B. Venugopal, A.J.M. van den Eertwegh, Sylvie Négrier, Howard Gurney, Laurence Albigès, Raanan Berger, John B.A.G. Haanen, Víctor Manuel Oyervides-Juárez, Brian I. Rini, James Larkin, Franco Nolè, M. Schmidinger, M.B. Atkins, Yoshihiko Tomita, B. Ellers-Lenz, Jason Hoffman, R. Sandner, J. Wang, A. di Pietro, R.J. Motzer - Annals of Oncology 2024 cited by 49

  24. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

    Authors: Philippe Rougier, R. Bugat, Jean‐Yves Douillard, Stéphane Culine, Etienne Suc, Pierre Brunet, Y. Bécouarn, Marc Ychou, M. Marty, Jean Marc Extra, Jacques Bonneterre, Antoine Adenis, Jean‐François Seitz, G. Ganem, M. Namer, Thierry Conroy, Sylvie Négrier, Yacine Merrouche, F Bürki, M Mousseau, Patrice Herait, Mondher Mahjoubi - Journal of Clinical Oncology 1997 cited by 433